Guardant Health reports 36% revenue growth in Q3 2026

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2026, Guardant Health, Inc. (the "Company") issued a press release announcing financial results for the fiscal quarter ended September 30, 2026.^{1 1}The full text of the press release is furnished as Exhibit 99.1¹ to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934², as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press release of Guardant Health, Inc., dated November 5, 2026³

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)³

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GUARDANT HEALTH, INC.

Date: November 5, 2026 By: /s/ Michael Bell⁴

Michael Bell⁴

Chief Financial Officer⁴

(Principal Financial Officer)

Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Third quarter 2026 revenue growth of 36% driven by strong performance in Oncology and Screening

Raises 2026 revenue guidance to $1.36 to $1.37 billion, representing growth of 38% to 40%⁷

PALO ALTO, Calif. November 5, 2026 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

For the three-month period ended September 30, 2026, as compared to the same period of 2025:

• Reported total revenue of $361.0 million, an increase of 36%, driven by:

◦ Oncology revenue of $231.3 million, an increase of 25%, and 117,000 oncology tests, an increase of 58%⁸

◦ Biopharma & Data revenue of $59.0 million, an increase of 8%

Recent Operating Highlights

• Received U.S. Food and Drug Administration (FDA) approval and CE-marking in Europe for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH (camizestrant), the first FDA approval of a liquid biopsy companion diagnostic for longitudinal testing in breast cancer

• Received FDA approval for Guardant360 CDx as a companion diagnostic for INLURIYO (imlunestrant) in combination with VERZENIO (abemaciclib) for eligible patients with ESR1-mutated advanced or metastatic breast cancer

• Submitted a premarket approval (PMA) application to the FDA for Guardant360 Tissue

• Launched Guardant Reveal Ultra with biopharma partners and remain on track for clinical launch in 2026

• Expanded commercial coverage for Shield to more than 80% of eligible lives, with key additions including UnitedHealth Group, Carelon Healthcare Services, and EviCore

• Successfully deployed the new FDA-approved lower COGS, higher-throughput Shield workflow

"Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma," said Helmy Eltoukhy, co-founder and co-CEO. "Oncology volume grew 58% with broad contributions across our portfolio. The FDA approval of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast cancer patients, ushering in a new paradigm of cancer treatment. It reinforces the role of Guardant360 in enabling earlier therapy decisions and strengthens our leadership across the cancer care continuum."

"Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests," said AmirAli Talasaz, co-founder and co-CEO. "Commercial coverage continues to expand, with recent policy updates extending Shield coverage to approximately 100 million lives. With our lower COGS, higher-throughput workflow now fully implemented, we have a strong operational foundation to meet future Shield demand. Together, these advances expand access to Shield and move us closer to making blood-based cancer screening a routine part of preventive care."

1

Third Quarter 2026 Financial Results

Revenue was $361.0 million for the third quarter of 2026, a 36% increase from $265.2 million for the corresponding prior year period.⁵ Oncology revenue grew 25% to $231.3 million for the third quarter of 2026⁶, from $184.4 million for the corresponding prior year period, driven primarily by an increase in Oncology test volume, which grew 58% over the prior year period. Screening revenue grew 180% to $67.6 million for the third quarter of 2026⁶, from $24.1 million for the corresponding prior year period, driven primarily by an increase in Shield test volume, which grew to 83,000 tests in the third quarter of 2026, from 24,000 tests in the prior year period⁸. Biopharma & Data revenue grew 8% to $59.0 million for the third quarter of 2026⁶, from $54.7 million for the corresponding prior year period. Licensing and other revenue was $3.1 million for the third quarter of 2026, compared to $2.0 million for the corresponding prior year period.

Gross profit, or total revenue less cost of revenue, was $236.2 million for the third quarter of 2026, an increase of $64.5 million or 38%, from $171.6 million for the corresponding prior year period. Gross margin, or gross profit divided by total revenue, was 65% for the third quarter of 2026⁹, as compared to 65% for the corresponding prior year period.

Non-GAAP gross profit was $240.2 million for the third quarter of 2026, an increase of $65.9 million or 38%, from $174.3 million for the corresponding prior year period. Non-GAAP gross margin was 67% for the third quarter of 2026, as compared to 66% for the corresponding prior year period⁹.

Operating expenses were $368.9 million for the third quarter of 2026, as compared to $270.6 million for the corresponding prior year period.¹⁰ The year-over-year increase in operating expenses was primarily related to commercial infrastructure expansion and marketing activities to support Screening and Oncology growth and an increase in stock-based compensation. Non-GAAP operating expenses were $287.4 million for the third quarter of 2026, as compared to $228.9 million for the corresponding prior year period. The year-over-year increase in non-GAAP operating expenses was primarily related to commercial infrastructure expansion and